ArticleCancers2025
Clinical Characteristics and Survival of Ovarian Cancer Patients According to Homologous Recombination Deficiency Status.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Role of Homologous Recombination Deficiency (HRD) in Renal Cell Carcinoma (RCC): Biology, Biomarkers, and Therapeutic Opportunities.Current oncology (Toronto, Ont.) · 2025Review
- Assessing the Impact of Patient Selection and Analytical Methods on mRNA Biomarker Identification in Ovarian Cancer Using TCGA Data.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHRD is a key biomarker in ovarian cancer, predicting response to PARP inhibitors. However, it remains unclear whether HRD-positive patients differ from HRD-negative patients in terms of clinical characteristics in PARP inhibitor-naïve populations. This study aims to evaluate platinum-sensitive PARP-inhibitor naïve ovarian cancer patients' clinical characteristics and survival outcomes based on HRD status. Secondly, to investigate whether platinum-resistant patients with homologous recombination repair (HRR) gene mutations are HRD-positive.
methodsTwo distinct HRD algorithms-an in-house genomic instability score (GIS) and the normalized large-scale state transitions score (nLST)-were used to stratify patients as HRD-positive or HRD-negative. Clinical data and survival in PARP inhibitor-naïve, platinum-sensitive HGSC patients were analyzed.
resultsA total of 71 platinum-sensitive PARP-inhibitor naïve patients were analyzed. By in-house GIS, 37 patients (52%) were classified as HRD-positive and 34 (48%) as HRD-negative. Using nLST, 43 (61%) were HRD-positive and 28 (39%) were HRD-negative. Our analysis revealed no significant differences in clinical parameters or survival between HRD-positive and HRD-negative platinum-sensitive patients. The only observed difference was that somatic
conclusionsOur findings suggest that HRD status does not significantly influence clinical characteristics or survival outcomes in platinum-sensitive, PARP inhibitor-naïve HGSC patients. As some platinum-resistant patients with HRR gene mutations were HRD positive; this subgroup may benefit from further investigation into the potential effect of PARP inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.